EIGR

Eiger BioPharmaceuticals Inc
2.26
0.16 (7.62%)

Eiger BioPharmaceuticals Inc. (EIGR) Fundamentals

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
SHARE INFORMATION
Market Cap$ 92,555,996
Shares Outstanding44,074,284
Float36,567,796
Percent Float82.97%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 12,142,000
Latest Fiscal EPS$ -1.01
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions223
Institutional Holdings Date2023-01-31
Institutional Bought Previous 3 Months2,028,747
Institutional Holdings Percent106.7%
Institutional Sold Previous 3 Months2,764,948
Insider Holdings Date2023-01-31
Insider Bought Previous 3 Months208,250
Insider Holdings Percent1.4
Insider Sold Previous 3 Months27,500
Insider Shares Owned608,836
TRADING INFO
52 Week High$ 10.02
52 Week Low$ 0.96
52 Week High Change$ -50.59
21 Day Moving Average$ 1.5005
21 Day Extended Moving Average$ 1.659
50 Day Moving Average$ 1.9934
50 Day Extended Moving Average$ 2.2177
200 Day Moving Average$ 5.663
200 Day Extended Moving Average$ 4.7791
10 Day Average Volume793,944
20 Day Average Volume732,321
30 Day Average Volume805,612
50 Day Average Volume1,167,362
Alpha-0.005550
Beta1.9203
Standard Deviation0.266772
R20.151173
7 Day Price Change$ 0.68
7 Day Percent Change47.89%
21 Day Price Change$ 0.60
21 Day Percent Change40.0%
30 Day Price Change$ 0.86
30 Day Percent Change69.35%
Month to Date Price Change$ 0.20
Month to Date Percent Change10.53%
Quarter to Date Price Change$ 0.92
Quarter to Date Percent Change77.97%
180 Day Price Change$ -7.22
180 Day Percent Change-77.47%
200 Day Price Change$ -6.03
200 Day Percent Change-74.17%
Year to Date Price Change$ 0.92
Year to Date Percent Change77.97%

Eiger BioPharmaceuticals Inc. (EIGR) Key Ratios

PROFITABILITY
EBIT Margin-633.0%
EBITDA Margin-627.1%
Pre-Tax Profit Margin0.0%
Profit Margin Count-35.57%
Gross Margin88.1%
Profit Margin TOT-35.57%
INCOME STATEMENTS
Revenue$ 10,788,000
Revenue Per Share$ 0.2448
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.20
Total Debt To Equity0.50
Int Coverage-23.50
Current Ratio5.40
Leverage Ratio1.70
Quick Ratio4.70
Long Term Debt To Capital0.33
VALUATION MEASURES
PE Ratio-0.90
Enterprise Value$ 11,105,996
Price to Sales8.5795
Price to Free Cash-1.50
PE High Last 5 Years-1.00
Price To Book1.20
Price To Cash Flow0.00
PE Low Last 5 Years-2.50
Price to Tangible Book1.20
MANAGEMENT EFFECTIVENESS
Receivables Turnover2.20
Invoice Turnover0.60
Assets Turnover0.00
Return Assets-65.77
Return on Equity-111.35
Return on Capital-76.31

Eiger BioPharmaceuticals Inc. (EIGR) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorKPMG LLP
CEODavid Apelian
Emplyoees54
Last AuditUQ
CIK0001305253
IndustryBiotechnology
SectorHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing(325414)
CONTACT INFO
Address2155 Park Boulevard
Palo Alto, CA 94306
Websitehttps://www.eigerbio.com
Facsimile+1 650 618-1621
Telephone+1 650 272-6138
Emailinfo@eigerbio.com


Your Recent History
NASDAQ
EIGR
Eiger BioP..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.